Shock due to trauma, infection and heart attack affects 10 million patients in USA and EU annually. Prof. Johansson at Rigshospitalet has identified a subgroup (20%) of the shocked patients having TOXic catecholamine release to the blood resulting in acute heart failure with >80% mortality rate. The shocked TOX patients can be identified by the biomarker succinic acid > 10nM in the blood enabling targeted treatment with beta1-selective blocker, which according to published observational data, will reduce mortality by 50%. A PCT application has been filed by Rigshospitalet concerning this[WO2022/233994 A1]. The TOX project will validate the 10nM cut-off level of succinic acid to identify TOX in 500 patients with septic shock by mass spectrometry using an existing biobank at Rigshospitalet. A point-of-care biosensor will be developed at DTU Bioengineering that measure succinic acid in plasma in the required nM range to be used in a proof-of-concept trial in 200 TOX patients with septic shock evaluating the effect of beta1-selective blockers vs. placebo on 30-day mortality conducted at Copenhagen University Hospitals. The result of the trial including a Health Technology Assessment conducted by VIVE will be used to implement the TOX test globally through license agreements, partnering or take-over with global diagnostic companies, and MoxieLab ApS, a spin-out from Rigshospitalet, now owning the IP. Roche Diagnostics has already shown interest in the technology.

Kombineret i-planen (langsgående) og ud-af-planen-forskydning (tværgående) begrænser bæreevnen af mange eksisterende betonbroer. Da mængden af forskning inden for dette emne er stærkt begrænset, er tilgængelige modeller opstillet som konservative estimater, hvilket kan føre til unødvendig udskiftning. Projektets formål er at udvikle en præcis forskydningsmodel og opstille en forstærkningsstrategi. Derfor skal der etableres detaljeret eksperimentel evidens for bæreevne og brudmekanismer.

Projekt søger at udvikle modeller der kan bestemme niveauet af kommunikationsbesvær for folk med høretab. Data fra laboratorier og fra den virkelige verden benyttes, så modellerne kan evalueres under forskellige forhold. I den virkelige verden opsamles data vha. høreapparater, sensorer, og smartphones, og in-situ spørgeskemaer benyttes til at forstå oplevet kommunikationsbesvær. Forskellige høreapparatindstillinger vil blive anvendt for at fastslå modellernes sensitivitet.